Oragenics Inc. (NYSE American: OGEN) has filed its Annual Report on Form 10-K for the year ended December 31, 2025, accompanied by a shareholder update detailing operational, clinical, and financial progress. The clinical-stage biotechnology company reported achieving several key milestones in 2025, including restoring compliance with NYSE American listing standards, completing a $16.5 million capital raise, transitioning its drug manufacturing to the United States, and advancing its lead candidate, ONP-002.
The company's ONP-002 program represents a potential first-in-class treatment for concussion and mild traumatic brain injury, utilizing Oragenics' proprietary intranasal delivery technology designed to target therapeutics to the brain. According to the update, Oragenics is working toward initiating a Phase IIa clinical trial for ONP-002 in Australia, with U.S. Phase 2b trials planned to follow. Early 2026 progress has been focused on patient enrollment and U.S. regulatory advancement for this program.
Beyond its lead candidate, Oragenics' intranasal delivery platform holds potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, post-traumatic stress disorder, and anxiety disorders. The company's strategic priorities, as outlined, include expanding its central nervous system pipeline to address these significant unmet medical needs in neurological care.
The operational update and full financial details are available in the company's recently filed Form 10-K. For more information about Oragenics and its development programs, visit https://oragenics.com. The latest news and updates relating to OGEN are also available in the company's newsroom at https://ibn.fm/OGEN.
For business and technology leaders, Oragenics' progress signals ongoing innovation in the biotechnology sector, particularly in the challenging area of neurological drug development. The transition to U.S.-based manufacturing and the strategic capital raise provide a foundation for advancing clinical trials. The advancement of a novel intranasal delivery platform could have broader implications for the pharmaceutical industry, potentially offering a new pathway for treating brain disorders that have been difficult to address with traditional delivery methods. The company's focus on concussion treatment also addresses a growing public health concern with significant societal and economic impacts.
